AmpliPhi Biosciences Corporation (OTCQB: APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. The company’s product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is currently collaborating with a number of leading organizations – including Intrexon Corporation (XON), the U.S. Army, The Royal Brompton Clinic in London, and the University of Leicester – to rapidly advance its bacteriophage-based therapies. For more information, visit the company’s website at www.ampliphibio.com.